January 31, 2024 02:48 PM EST
R&D
FDA+

Apoc­a­lypse or rip­ple? Ahead of first of­fers on price, new re­search pre­dicts IRA im­pact on R&D will be mod­est

Zachary Brennan

Senior Editor

Ever since the In­fla­tion Re­duc­tion Act was signed in­to law by Pres­i­dent Joe Biden in Au­gust 2022, bio­phar­ma com­pa­nies have lev­eled at­tacks on it, ar­gu­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times